Schistosomiasis vaccine - Glaxo Wellcome/Medeva

Drug Profile

Schistosomiasis vaccine - Glaxo Wellcome/Medeva

Latest Information Update: 16 Oct 2007

Price : $50

At a glance

  • Originator Evans Vaccines; GlaxoSmithKline; Institut Pasteur
  • Developer Evans Vaccines; GlaxoSmithKline; Nonindustrial source
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Schistosomiasis

Most Recent Events

  • 16 Oct 2006 Discontinued - Preclinical for Schistosomiasis in United Kingdom (unspecified route)
  • 15 Jun 2001 No-Development-Reported for Schistosomiasis in United Kingdom (Unknown route)
  • 10 Jan 1995 Preclinical development for Schistosomiasis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top